drugset / Trial / NCT04792567
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on treatment with first-line DMTS or no current MS treatment..
Timeline
- Start
- 2021-04-19
- Primary completion
- 2021-09-06
- Completion
- 2022-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAF312 | Unknown | 1 mg | Oral |
| Subject | BAF312 | Unknown | 2 mg | Oral |
| Subject | BNT162b2 | Messenger RNA (mRNA) | — | — |
| Subject | Elasomeran | Messenger RNA (mRNA) | — | — |
| Comparator | Glatiramer Acetate | Small molecule | — | — |
| Comparator | dimethyl fumarate | Unknown | — | — |
| Comparator | teriflunomode | Unknown | — | — |